BBAGF OTC
BB Biotech AG
1W: +0.0%
1M: +31.8%
3M: +0.0%
YTD: +0.0%
1Y: +3.9%
3Y: +14.9%
$64.36
+3.18 (+5.20%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$112M
+157.6% ▲
5Y CAGR: -30.4%
Gross Profit
$112M
+155.9% ▲
5Y CAGR: -30.4%
Operating Income
$84M
+140.9% ▲
5Y CAGR: -34.1%
Net Income
$76M
+136.7% ▲
5Y CAGR: -35.5%
EPS (Diluted)
$1.38
+136.6% ▲
5Y CAGR: -35.4%
EBITDA
$80M
+140.0% ▲
5Y CAGR: -34.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $699M | -$395M | -$350M | -$194M | $112M |
| YoY Growth | +2.0% | -156.5% | +11.6% | +44.6% | +157.6% |
| Cost of Revenue | $883K | $986K | $2M | $0 | $0 |
| Gross Profit | $699M | -$396M | -$351M | -$200M | $112M |
| Gross Margin | 100.0% | 100.2% | 100.5% | 103.0% | 100.0% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7M | $7M | $5M | $6M | $27M |
| Operating Expenses | $8M | $9M | $7M | $7M | $27M |
| Operating Income | $700M | -$53M | -$39M | -$207M | $84M |
| Operating Margin | 100.1% | 13.3% | 11.1% | 106.6% | 75.6% |
| Interest Expense | $883K | $986K | $2M | $6M | $5M |
| Income Before Tax | $691M | -$405M | -$358M | -$207M | $76M |
| Tax Expense | $75K | $67K | $61K | $79K | $54K |
| Net Income | $691M | -$405M | -$358M | -$207M | $76M |
| Net Margin | 98.8% | 102.4% | 102.4% | 106.6% | 68.0% |
| EPS (Diluted) | $12.48 | $-7.31 | $-6.50 | $-3.77 | $1.38 |
| EBITDA | $691M | -$405M | -$351M | -$201M | $80M |
| Shares Outstanding | 55M | 55M | 55M | 55M | 55M |